Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease (Q33715510)

28 July 2017

title

Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease (English)

1 reference

28 July 2017

Bradley A Warady

1 reference

28 July 2017

Nicholas J A Webb

1 reference

28 July 2017

Gary Lerner

1 reference

28 July 2017

Katherine M Dell

1 reference

28 July 2017

Larry A Greenbaum

1 reference

28 July 2017

Gema Ariceta

1 reference

28 July 2017

Bernd Hoppe

1 reference

28 July 2017

Peter Linde

1 reference

28 July 2017

Ho-Jin Lee

1 reference

28 July 2017

Ann Eldred

1 reference

28 July 2017

Matthew B Dufek

1 reference

28 July 2017

publication date

22 March 2017

1 reference

28 July 2017

1 reference

28 July 2017

1 reference

28 July 2017

1 reference

28 July 2017

page(s)

1221-1232

1 reference

Creative Commons Attribution 4.0 International

28 July 2017

start time

22 March 2017

1 reference

April 2022 Public Data File from Crossref

copyrighted

0 references

cites work

Treatment Failure of Active Vitamin D Therapy in Chronic Kidney Disease: Predictive Factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5440538

Prevalence and correlates of 25-hydroxyvitamin D deficiency in the Chronic Kidney Disease in Children (CKiD) cohort

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5440538

KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5440538

New equations to estimate GFR in children with CKD

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5440538

Chronic kidney disease mineral and bone disorder in children

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5440538

Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5440538

Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5440538

"High-dose" calcitriol for control of renal osteodystrophy in children on CAPD.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5440538

Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00467-017-3579-6

Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00467-017-3579-6

K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5440538

Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5440538

A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5440538

Hyperparathyroidism and 1,25-Dihydroxyvitamin D Deficiency in Mild, Moderate, and Severe Renal Failure*

30 October 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00467-017-3579-6

Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality

21 January 2018

1 reference

12 December 2020

Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease

1 reference

12 December 2020

Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis

1 reference

12 December 2020

Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease

1 reference

12 December 2020

Renal bone disease in pediatric and young adult patients on hemodialysis in a children's hospital

1 reference

12 December 2020

Arterial stiffening and vascular calcifications in end-stage renal disease

1 reference

12 December 2020

Pathogenesis of secondary hyperparathyroidism

1 reference

12 December 2020

Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis

1 reference

12 December 2020

Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD

1 reference

12 December 2020

10.1007/S00467-017-3579-6

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference